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emphasize the importance of antigen-speciﬁc activation in the
selectivity of PDT for alloreactive T cells. Preservation of func-
tional T and B cells post-transplant should translate into protec-
tion against infectious agents and tumor cells.
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COMPLETE CHIMERISM FOLLOWING THE USE OF ANTI-CD33 ANTI-
BODY IN A CHILD WITH RELAPSED ACUTE LYMPHOCYTIC LEUKEMIA
(ALL) AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION (allo
BMT)
Odone-Filho, V.; Carvalho, A.; Ramos, R.R.; Conchon, M.; Cristofani,
L.M. Hospital Sirio Libanes, Sao Paulo, SP, Brazil.
The monoclonal anti-CD33 antibody (gemtuzumab ozogamicin:
GO) represents a therapeutic option for leukemic patients with
CD33-positive disease. Few reports relate its action in patients
with ALL who anomalously express CD33. We here report
GDRT, WM, diagnosed at the age of 4 years as having standard-
risk ALL, whose immunophenotypic expression included: CD34,
HLA-DR, TdT, CD19, CD79a, CD10 and also ectopic presence
of the myeloid antigens CD13 and CD33, treated as per the
Brazilian Cooperative Protocol-93, including: VCR, DEXA,
DAUNO, ASP and ARA-C as induction, high-dose MTX as in-
tensiﬁcation, maintenance with 6-MP, regular and high-dose
MTX and prophylactic intrathecal triple drugs (MADIT: MTX 
ARA-C  DEXA). Unsuccessful reinduction trials elicited by a
marrow recurrence after 12 months in remission were followed by
an allo-BMT, with active disease, the source of cells being the
cord-blood of his HLA-compatible sister. He did achieve a com-
plete engraftment, with normal XX marrow cells, which unfortu-
nately lasted less than 4 months. He was then referred with fully
active disease, over 60,000 blast cells/cu. mm., XX/XY chimera,
with the same initial immunophenotypic expression, hepatospleno-
megaly and adenomegaly, normal CSF and sepsis. Reinduction was
attempted with 8 cycles of VM-26 and ARA-C in 4 weeks followed
by TOPO and ETO, besides MADIT. Although there had been
disappearance of organomegaly and peripheral blast cells after the
3rd VM-26/ARA-C cycle, the marrow remained an M3 one even
13 days after TOPO/ETO exposure. Considering his anomalous
CD33 expression, GO, 3 mg/sq. m., 1-hour iv infusion was then
given. Marrow aplasia was veriﬁed after 7 days and an M1 marrow,
fully XX, was seen after 18 days. Maintenance plans included
monthly cycles of GO, as above, plus MADIT. Marrow sample
obtained at the 8th week after documented remission revealed
again blast cells, whose immunophenotypic expression continued
being the same, except for CD33 negativity. At the time of this
report the child continued being followed as outpatient, with
clearly progressive disease, however receiving only transfusional
support, with no additional therapeutic attempts. Interestingly, his
peripheral blood cells continued mostly being XX ones. GO was
capable of reproducing in a child with ALL and anomalous CD33
expression a complete chimera anteriorly obtained after an allo-
BMT. This might be an option for non-ablative procedures with
stem-cell reinfusion support.
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DEVELOPEMENT OF CHRONIC GVH IS THE STRONGEST PREDICTOR OF
SURVIVAL IN PATIENTS WITH POOR-RISK AML IN REMISSION AFTER
RELATED OR UNRELATED SCT
Fibich, C.1; Luiders, J.2; Douglas, S.2; Robert, T.A.2; Loree, L.2; Chris-
topher, B.2; Assan, C.2; James, R.A.2 1. Department of Hematology/
Oncology, Martin-Luther University, Halle/Saale, Germany; 2. Alberta
BMT Program, Calgary, AB, Canada.
High risk AML by clinical criteria, deﬁned as relapsed or refrac-
tory disease, primary induction-therapy failure, secondary AML or
advanced disease beyond 1st CR has a dismal outcome with all
current therapies. We analysed the inﬂuence of transplant-related
factors and GvHD on the outcome of adult pts with HR-AML who
underwent an allogeneic SCT in the Alberta Transplant Program.
Patients and methods: 105 adult pt median age 42, range 20 to 65y
were transplanted between 5/88 and 7/02. 71 pt received SCT
from related, 34 from matched unrelated donors. Indications for
allo-SCT were: 71 AML, 24 in 2nd CR, 18 refractory relapse, 15
primary induction failure and 14 untreated relapse. 34 pt had
secondary AML, either untreated (N26), refractory (N5) or
relapsed (N3). Conditioning-regimen used were: BuCy N43 (6
pt with ATG), CyTBI N17 (5 pt with ATG), FluBuATG N34,
VP16/TBI, N8, other N3. 62 pt received ATG (Sangstat,
Fresno, USA) and 31 pt TBI. Cytogenetic results were available for
23 adult pt at relapse or pre-BMT and for 25 pt at initial diagnosis.
Of these 3 were favorable (inv16, t8/21), 6 were normal karyotype,
and 8 other single translocations, and 29 were either complex
abnormal karyotype or high risk chromosomal aberrations (del 5q-,
del7). 3y OAS survival for all adult pt was 28% (95% CI: 20.03–
37.54%). No signiﬁcant differences in survival were found for
age-groups, cytogenetic risk-factors, MDS/AML vs AML, pres-
ence of aGvH I°. A trend for improved survival was found for pt
receiving TBI-containing regimen when compared to BuCY
(p0.064). The use of ATG in conditioning did not improve 100
d-OAS (no ATG 68.%, vs ATG 73%). Occurrence of cGvH
resulted in a highly signiﬁcant survival difference in favor of pts
with cGvH with a median survival of 760 vs 230 d (p0.002, HR
2.3) and a 3 y OAS of 47 vs 18% (p
0.01%). Chemotherapy-
intensity or donor-type did not signiﬁcantly inﬂuence outcome in
this poor-risk cohort. The only factor with highly signiﬁcant effect
on survival (p0.003) was the presence of chronic GvH suggesting
a graft vs leukemia effect requiring clinically evident GvH. The
beneﬁcial effect of ATG on early mortality that has been shown in
lower-risk pt-groups was not reproducible in this cohort possibly
due to the high early relapse rate (data not shown).
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ALLOGENEIC STEM CELL TRANSPLANTATION IN CHRONIC MYELOID
LEUKAEMIA: EXPERIENCE AT ARMED FORCES BONE MARROW TRANS-
PLANT CENTRE-PAKISTAN
Raza, S.; Hashmi, K.U.; Khattak, B.K.; Ahmed, P.; Hussain, I. Armed
Forces Bone Marrow Transplant Center, Rawalpindi, Punjab, Pakistan.
Objective: To evaluate the role and outcome of allogeneic stem
cell transplantation in chronic myeloid leukaemia in our popula-
tion. Methods: Cases suffering from chronic myeloid leukaemia
less than 50 years of age and having HLA matched sibling donor
received allogeneic stem cell transplantation. Conditioning was
done with busulphan 16 mg/kg plus cyclophosphamide 200 mg/kg
(Big Bu/Cy) or busulphan 16 mg/kg plus cyclophosphamide 120
mg/kg (Mini Bu/Cy), GVHD prophylaxis was given with Cyclo-
sporin (CSA) alone, or CSA plus Prednisolone with or without
short course of methotrexate. Patients received PBSC or bone
marrow alone or both. G-CSF was administered either on day 5
or 8 till ANC recovery. Engraftment was deﬁned as achievement
of neutrophil count of 0.5  109/l on 3 consecutive days. Pa-
tient’s engraftment and disease status were assessed at day 21, day
100 and thereafter every three months. Results: Since 5 April
2002 a total of 20 patients of chronic myeloid leukaemia underwent
allogeneic stem cell transplantation. Seventeen were male and 3
female. Median age of the patients was 29 years (range 7–50). 16
cases received PBSC, 1 bone marrow and 3 both. Mean mononu-
clear cell dose was 4.9  108/kg. Median time to neutrophil
recovery was 11.7 days (range 9–14). Neutropenic fever was seen in
80% cases, with mean duration of fever being 6.07 days. In ma-
jority no focus of infection was found. However cultures were
positive in 30% (n6) cases. Various isolates included gram-neg-
ative rods (n3); staphylococcus (n2) and fungi (n1) The com-
mon post engraftment infections were due to gram-negative rods,
tuberculosis, aspergillus, and herpes zoster. Other post-BMT com-
plications included acute GVHD 40%, chronic GVHD 15% and
hemorrhagic cystitis 15%. There were 4 (20%) deaths while in one
patient disease relapsed. Cause of death was septicaemia (n2),
DIC (n1) and disseminated aspergillosis (n1). The overall and
disease free survival (DFS) is 80% and 75% respectively. Mean
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follow up period is 14 months. Conclusion: Our initial experience
shows that allogeneic stem cell transplantation is an effective treat-
ment option in patients of chronic myeloid leukaemia in chronic
phase, who are less than 50 years of age and have HLA matched
sibling donor. This is in line with experience from other centers.
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PROGNOSTIC PROGENITOR PROFILING IN CHRONIC MYELOMONO-
CYTIC LEUKEMIA
Jamieson, C.H.M.1; Li, K.1; Gotlib, J.1; Coutre, S.E.1; Lagasse, E.2;
Weissman, I.L.1 1. Stanford University School of Medicine, Stanford,
CA; 2. University of Pittsburgh, Pittsburgh, PA.
Chronic myelomonocytic leukemia (CMML) is a unique myelo-
proliferative disease characterized by marrow dysplasia and an
increase in monocytes. The median survival of patients with
CMML is short, in part, because CMML is frequently resistant to
therapy. A better understanding of the basic biology of CMML
progenitors is needed in order to reduce regimen related toxicity
and provide more effective CMML targeted therapies. To this end,
a mouse transgenic model of CMML was created in which human
bcl-2 overexpression was targeted to the myeloid lineage by the
myeloid promoter hMRP8. Transgenic hMRP8-bcl2 mice devel-
oped a myeloproliferative disorder characterized by a monocytosis
in all hematopoietic tissues and splenomegaly. Myeloid progenitor
analysis of hMRP8-bcl-2 bone marrow revealed a marked ex-
pansion of human bcl-2 expressing granulocyte-macrophage
progenitors compared with control mice. In order to see if
this correlated with human CMML, we used FACS analysis
and recently identiﬁed phenotypic markers to identify pheno-
typic and functional differences between normal and CMML
bone marrow hematopoietic stem cells and myeloid pro-
genitors. CMML marrow was typiﬁed by a reduction in
CD34CD38CD90Lin hematopoietic stem cells and an ex-
pansion of CD34CD38CD90Flk2Lin cells relative to nor-
mal bone marrow. In addition, there was a two-fold expansion in
common myeloid progenitors (CMPs) and a corresponding de-
crease in megakaryocyte-erythroid progenitors (MEPs) suggesting
that there was a skew in differentiation toward the myeloid lineage.
In contrast to normal bone marrow derived CMPs, CMML CMPs
gave rise to myeloid but not erythroid colonies. Moreover, real
time quantitative RT-PCR analysis of highly puriﬁed FACS-sorted
CMML CMPs demonstrated increased expression of two key reg-
ulators of myelomonocytic differentiation, PU.1 and c-jun, com-
pared with normal bone marrow. A more detailed understanding of
the basic biology of CMML progenitors and the genes that work in
concert to expand them may aid in identifying novel molecular
targets for CMML.
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POST-REMISSION THERAPY OF ACUTE MYELOID LEUKEMIA IN FIRST
REMISSION
Kim, S.T.; Kim, K.; Lee, S.H.; Kim, W.S.; Jung, C.W.; Lee, M.H.;
Park, K. Hematology-Oncology, Samsung Medical Center, Sungkyunk-
wan University, Seoul, Korea.
Background: At AML in ﬁrst remission, treatment-modality
depends on patient’s prognostic factor and donor availability. Ac-
cording to the risk group of AML, post remission therapy has not
established. We analyzed the effect of post-remission therapy of
AML in ﬁrst remission, allogeneic, autologous HSCT and inten-
sive chemotherapy. Method: According to the post-remission
therapy, we retrospectively evaluated the prognostic factor, the
event-free survival (EFS) and the overall survival (OS) of 122
patients with AML in ﬁrst remission from 1995 to 2004. All
patients received standard induction therapy. After complete re-
mission had been achieved, consolidation therapy was started.
According to patients’ clinical status and donor availability, pa-
tients were offered the different treatment-modalities, allogeneic,
autologous HSCT or intensive chemotherapy. Result: Twenty-
ﬁve patients received allogeneic HSCT, 36 patients autologous
HSCT and 61 patients intensive chemotherapy. Median age was 33
years in allogeneic HSCT group, 38 years in autologous HSCT
group, and 46 years in intensive chemotherapy group. The 5-year
EFS were 72% in allogeneic HSCT group, 57% in the autologous
HSCT group and 50% in chemotherapy group (p0.049). When
comparing between treatment groups, there was no difference in
EFS. The 5-year OS rates were 80% in allogeneic HSCT group,
60% in autologous HSCT group and 53% in chemotherapy group
(p0.02). There was a signiﬁcant difference in OS only between
allogeneic HSCT group and chemotherapy group (p0.04). There
was an advantage in terms of EFS (p0.04) and OS (p0.03) with
HSCT as compared intensive chemotherapy. The EFS and OS of
allogeneic HSCT as compared with autologous HSCT has not
difference. There was a signiﬁcant beneﬁt for EFS and OS with
HSCT group when compared to those in intensive chemotherapy
group in the high risk group of AML patients (p
0.05). In the
intermediate and low risk group of AML, there was no signiﬁcant
difference in OS with HSCT as compared to the intensive chemo-
therapy, but a signiﬁcant beneﬁt for EFS of HSCT as compared
with the intensive chemotherapy (p
0.05). Conclusion: The
treatment of high risk-AML in ﬁrst remission with either alloge-
neic or autologous hematopoietic stem cell transplantation pro-
longs EFS and OS as compared with intensive chemotherapy. In
the intermediate or low risk-AML, there was a signiﬁcant beneﬁt
for only EFS with HSCT compared as intensive chemotherapy.
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ALLOGENEIC STEM-CELL TRANSPLANTATION IN PATIENTS WITH AML
AND MDS USING MYELOABLATIVE VERSUS REDUCED-INTENSITY
DOSES OF INTRAVENOUS BUSULFAN (BUSULFEX): THE ROLE OF DOSE
INTENSITY
Shimoni, A.; Yeshurun, M.; Hardan, I.; Avigdor, A.; Shem-Tove, N.;
Ben-Bassat, I.; Nagler, A. Chaim Sheba Medical Center, Tel-Hashomer,
Israel.
Allogeneic stem cell transplantation (SCT) is a potentially cura-
tive approach in patients (pts) with AML and MDS. Intravenous
busulfan (Busulfex, ivBu) reduces treatment-related mortality
(TRM) and improves outcome after standard ablative condition-
ing. Reduced-intensity regimens allow SCT in pts not eligible for
standard conditioning. It is not yet well established what are the
dose intensities of ivBu predicting of better outcome in different
settings. 91 pts were included in this analysis; median age 50 years
(range, 18–70). 77 had AML (33 secondary) and 14 had MDS. The
donors were HLA-matched siblings (n45), 1-Ag mismatched
relatives (n6) or matched-unrelated (n40). 42 pts were in ﬁrst
or second remission at SCT, or untreated with 
10% marrow
blasts; 49 were chemo-refractory or with 10% marrow blasts
(active disease). 43 pts had ablative conditioning with ivBu, 12.8
mg/kg (Bu16) and cyclophosphamide (Cy). 48 pts considered not
eligible for ablative therapy were given ﬂudarabine (Flu) and esca-
lated doses of ivBu, 6.4–12.8 mg/kg, (Bu8–16). With a median
follow-up of 14 months, the 2-year overall (OS) of all pts was 48%
(95 CI, 36–61). The cumulative incidence of TRM and relapse
were 15% and 39%, respectively. The most important predictive
factor for OS in multivariant analysis was active disease at SCT
(HR 3.7, p0.001). Age, gender, secondary AML/MDS, donor
type and regimen used were not signiﬁcant. There was no differ-
ence in OS between pts given different doses of ivBu. The OS of
pts given Bu16 (with Cy or Flu) was 49%, compared with 51% in
pts given Flu and Bu8–12. Pts given Bu16 had higher risk of TRM
(19% vs 7%) and lower relapse rate (34% vs 46%), not reaching
statistical signiﬁcance. However, ivBu dose had a signiﬁcant inﬂu-
ence in pts with active disease. OS, TRM and relapse rates were
45%, 22%, and 34% in pts given Bu16 compared with 0%
(p0.05), 18% (pNS), and 82% (p0.04) after Bu8–12, respec-
tively. In conclusion, ivBu containing regimens are well tolerated
with relatively low TRM rates. Dose intensity is not predictive of
outcome in chemo-sensitive disease. However, pts with active
disease could only be salvaged if given ablative doses of ivBu. Pts
considered not eligible for ablative conditioning tolerated Flu and
ablative doses of ivBu relatively well, and could be salvaged with
this regimen even when treated for active disease. Randomized
studies will be needed to further determine the best dose-intensity
in each setting.
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